Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer

Abstract

In recent years, numerous molecular-targeted drugs have become available for the perioperative therapy of breast cancer, bringing about a revolution in breast cancer treatment. Based on comprehensive gene expression analysis, breast cancer is classified into four subtypes, and there are limitations regarding the drugs that can be used depending on the subtype and the cancer progression. Therefore, it is necessary to identify and select the appropriate drugs for each subtype. This review explores the expanded indications of four recently available molecular-targeted drugs in breast cancer treatment.

Keywords

• subtype
• cdk 4/6 inhibitors
• immune checkpoint inhibitors
• anti-her2 drug
• parp inhibitors